ENO2 and sporadic Creutzfeldt-Jakob disease: Compared with sporadic CJD (sCJD), fCJD with V180I showed (1) older onset age, (2) slower disease progression, (3) unique clinical symptoms such as frequent cognitive dysfunction without visual or cerebellar symptoms, (4) a lower positive rate of NSE and 14-3-3 protein in CSF, and (5) a lack of PSD in EEG throughout the course of the disease [7].